Graham CN, Hechmati G, Hjelmgren J, et. al. Cost-effectiveness analysis of panitumumab plus mFOLFOX6 compared with bevacizumab plus mFOLFOX6 for first-line treatment of patients with wild-type RAS metastatic colorectal cancer. Eur J Cancer. 2014 Sep 11. [Epub ahead of print] PubMed PMID: 25219451.
|Image by the Italian voice via Flickr CC BY 2.0|
Leleu H, Blachier M, Rosa I. Cost-effectiveness of sofosbuvir in the treatment of patients with hepatitis C. J Viral Hepat. 2014 Sep 15. [Epub ahead of print] PubMed PMID: 25219291.
Kiadaliri AA, Gerdtham UG, Eliasson B, et. al. Cost-Utility Analysis of Glucagon-Like Peptide-1 Agonists Compared with Dipeptidyl Peptidase-4 Inhibitors or Neutral Protamine Hagedorn Basal Insulin as Add-On to Metformin in Type 2 Diabetes in Sweden. Diabetes Ther. 2014 Sep 12. [Epub ahead of print] PubMed PMID: 25213800.
Seguí MA, Crespo C, Cortés J, et. al. Genomic profile of breast cancer: cost-effectiveness analysis from the Spanish National Healthcare System perspective.Expert Rev Pharmacoecon Outcomes Res. 2014 Sep 12:1-11. [Epub ahead of print] PubMed PMID: 25213317.